675616-59-8

Basic information

• Product Name: 5-O-(2,3,4-tri-O-acetyl-6-deoxy-6-fluoro-β-D-glucopyranosyl)-6,3',4'-tri-O-benzyl-1,3,2',6'-tetraazidoneamine
• Synonyms: 5-O-(2,3,4-tri-O-acetyl-6-deoxy-6-fluoro-β-D-glucopyranosyl)-6,3',4'-tri-O-benzyl-1,3,2',6'-tetraazidoneamine
• CAS NO: 675616-59-8
• Molecular Weight: 986.971
• Mol File: 675616-59-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-O-(2,3,4-tri-O-acetyl-6-deoxy-6-fluoro-β-D-glucopyranosyl)-6,3',4'-tri-O-benzyl-1,3,2',6'-tetraazidoneamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-O-(2,3,4-tri-O-acetyl-6-deoxy-6-fluoro-β-D-glucopyranosyl)-6,3',4'-tri-O-benzyl-1,3,2',6'-tetraazidoneamine(675616-59-8)
• EPA Substance Registry System: 5-O-(2,3,4-tri-O-acetyl-6-deoxy-6-fluoro-β-D-glucopyranosyl)-6,3',4'-tri-O-benzyl-1,3,2',6'-tetraazidoneamine(675616-59-8)

Safety Data

• Hazardous Substances Data: 675616-59-8(Hazardous Substances Data)

Upstream product

• 4577-39-3 methyl 6-deoxy-6-fluoro-α-D-glucopyranoside 
• 31337-78-7 1,2,3,4-Tetra-O-acetyl-6-deoxy-6-fluoro-D-glucofuranose 
• 236115-80-3 1,3,2',6'-tetraazido-6,3',4'-tri-O-benzyl neamine 
• 674782-59-3 2,3,4-tri-O-acetyl-6-deoxy-6-fluoro-α-D-glucopyranosyl trichloroacetimidate 

Relevant articles and documents

Application of the Synthetic Aminosugars for Glycodiversification: Synthesis and Antimicrobial Studies of Pyranmycin

A divergent approach was employed for the synthesis of aminosugars, from which a novel library of aminoglycoside antibiotics (pyranmycins) was synthesized. Pyranmycins have comparable antibacterial activity as neomycin, a clinically used aminoglycoside antibiotic, against Escherichia coli, Staphylococcus aureus, Bacillus subtilis, and Mycobacterium smegmatis. In addition, pyranmycins, like streptomycin, are bacteriocidal while isoniazid (INH) is bacteriostatic. Therefore, pyranmycins may provide new therapeutic options in the treatment against tuberculosis. Several members of pyranmycins also manifest modest anti-Tat and anti-Rev activities, which may aid in the development of new anti-HIV agents. Although the antibacterial activity of pyranmycins against aminoglycoside resistant bacteria is less than expected, the synthetic methodologies of utilizing a library of aminosugars can be a model for future studies of glycodiversification or glycorandomization.